Therefore, JAKis, TNF inhibitors, and non-TNF inhibitors are recommended for RA patients who show inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) through a shared decision-making process between patients and physicians [9,10]. Here, TNF is linked to rheumatoid arthritis.